☰ Accessibility

Apollo Micro Systems Limited has allotted 35,088 equity shares at ₹114 per share to Mr. Piyush Bhupendra Gala, a non-promoter, following the conversion of warrants. This allotment is part of a larger preferential issue of 3,80,67,058 convertible equity warrants. The company’s paid-up capital has now increased to ₹33,56,74,736. Proceeds from the preferential issue, totaling ₹434.80 crore, are earmarked for working capital, R&D, and general corporate purposes, with Acuite Ratings & Research Limited confirming proper utilization.

Key Details of the Allotment

  • Allottee: Mr. Piyush Bhupendra Gala (Non-Promoter)
  • Number of Shares Allotted: 35,088
  • Face Value: Re. 1 per share
  • Issue Price: ₹114 per share (including ₹113 premium)
  • Amount Received: ₹40,00,032

Updated Share Capital:

  • Paid-up capital increased from ₹33,56,39,648 to ₹33,56,74,736
  • Total equity shares now: 33,56,74,736 shares of Re. 1 each

Warrant Conversion Details

  • Total Warrants Allotted: 3,80,67,058 convertible equity warrants
  • Current Conversion: 35,088 warrants
  • Conversion Price: ₹114 per warrant
  • Payment Structure:
    • Upfront 25% at subscription: ₹28.50 per warrant
    • Balance 75% at conversion: ₹85.50 per warrant

Utilization of Preferential Issue Proceeds

Funds from the preferential issue are being deployed for:

  1. Working Capital Requirements
  2. Research & Development
  3. General Corporate Purposes (includes ₹4.13 crore consultancy charges)

Monitoring Agency Confirmation: Acuite Ratings & Research Limited verified the proper utilization of funds.

Remaining Warrants

  • Previously Converted: 21,07,194 warrants
  • Converted in Current Allotment: 35,088 warrants
  • Unexercised Warrants: Will lapse if not converted within six months from the date of allotment.

Summary:
Apollo Micro Systems completed the partial conversion of warrants, allotting 35,088 equity shares and increasing paid-up capital to ₹33.56 crore. The preferential issue proceeds are being used as planned for working capital, R&D, and corporate purposes, with proper monitoring in place. Remaining warrants must be converted within six months or lapse.

Disclaimer:

This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.

Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.